The NICHE phase 2 trial aimed to investigate 3-year DFS in patients with dMMR colon cancer treated with neoadjuvant ipilimumab and nivolumab. The primary endpoint were to determine safety and DFS. Researchers observed 100% 3-year DFS in dMMR colon cancer with neoadjuvant ipilimumab and nivolumab, supported by negative ctDNA. Patients with MMR-deficient (dMMR) […]